Beelen D W, Graeven U, Schulz G, Grosse-Wilde H, Doxiadis I, Schaefer U W, Quabeck K, Sayer H, Schmidt C G
Department of Internal Medicine (Tumor Research), West German Tumor Center, University Hospital Essen, FRG.
Onkologie. 1988 Feb;11(1):56-8. doi: 10.1159/000216484.
As part of an ongoing phase-I/II trial, 2 patients received a 5-day treatment course with a murine monoclonal antibody (MAB) directed against the human T cell receptor (BMA031) as primary therapy of acute grade III skin and gastro-intestinal graft-versus-host disease (GvHD) occurring after allogeneic bone marrow transplantation (BMT). All MAB infusions were tolerated without side effects. A complete response of all symptoms of acute GvHD could be attained by MAB therapy under a continued baseline immunosuppression with cyclosporin (CSP), and both patients remain alive and disease-free at 7 and 8 months after therapy without evidence of chronic GvHD. Although the exact treatment scheme has still to be defined, we conclude that this MAB may be useful as primary therapy of acute GvHD. However, the potential hazards of 'in vivo' therapy with MABs directed against T lymphocytes call for a critical evaluation of this treatment modality.
作为一项正在进行的I/II期试验的一部分，2例患者接受了为期5天的治疗疗程，使用一种针对人类T细胞受体的鼠单克隆抗体（MAB，BMA031）作为异基因骨髓移植（BMT）后发生的急性III级皮肤和胃肠道移植物抗宿主病（GvHD）的主要治疗方法。所有MAB输注均耐受，无副作用。在持续使用环孢素（CSP）进行基线免疫抑制的情况下，MAB治疗可使急性GvHD的所有症状完全缓解，两名患者在治疗后7个月和8个月时均存活且无疾病，无慢性GvHD迹象。尽管确切的治疗方案仍有待确定，但我们得出结论，这种MAB可能作为急性GvHD的主要治疗方法有用。然而，针对T淋巴细胞的MAB“体内”治疗的潜在风险需要对这种治疗方式进行严格评估。
